Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Smith MA, Licata T, Lakhani A, Garcia MV, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk AC, Chen YA, Creelan BC, Boyle TA, Haura EB.

Clin Cancer Res. 2017 Nov 15;23(22):7084-7096. doi: 10.1158/1078-0432.CCR-16-3006. Epub 2017 Aug 29.

2.

Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.

Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB.

Sci Signal. 2015 Jan 13;8(359):ra4. doi: 10.1126/scisignal.2005906.

3.

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

Maier A, Peille AL, Vuaroqueaux V, Lahn M.

Cell Oncol (Dordr). 2015 Apr;38(2):131-44. doi: 10.1007/s13402-014-0210-8. Epub 2015 Jan 9.

4.

VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities.

Andreozzi M, Quagliata L, Gsponer JR, Ruiz C, Vuaroqueaux V, Eppenberger-Castori S, Tornillo L, Terracciano LM.

Angiogenesis. 2014 Jul;17(3):519-27. doi: 10.1007/s10456-013-9396-z. Epub 2013 Oct 11.

PMID:
24114200
5.

Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents.

Fiebig HH, Vuaroqueaux V, Korrat A, Foucault F, Beckers T.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):70-1. No abstract available.

6.

Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR.

Morant R, Vuaroqueaux V, Diener PA, Fürstenberger G, Horica C, Németh T, Sulmoni M, Eppenberger U, Eppenberger-Castori S.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):86-7. No abstract available.

PMID:
21176740
7.

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.

8.

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW.

Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166.

9.

Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group.

Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, Martens JW.

Eur J Cancer. 2009 Jan;45(1):74-81. doi: 10.1016/j.ejca.2008.09.030. Epub 2008 Nov 12.

PMID:
19008094
10.

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, Eppenberger-Castori S.

Breast Cancer Res. 2007;9(3):R33.

11.

Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.

Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.

J Clin Oncol. 2006 Sep 10;24(26):4245-53.

PMID:
16963728
12.

Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples.

Zanetti-Dällenbach R, Vuaroqueaux V, Wight E, Labuhn M, Singer G, Urban P, Eppenberger U, Holzgreve W, Eppenberger-Castori S.

Breast Cancer Res. 2006;8(4):R51.

13.

11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M, Dutour A, Grino M.

Obesity (Silver Spring). 2006 May;14(5):794-8.

14.

Expression of adrenomedullin in adipose tissue of lean and obese women.

Paulmyer-Lacroix O, Desbriere R, Poggi M, Achard V, Alessi MC, Boudouresque F, Ouafik L, Vuaroqueaux V, Labuhn M, Dutourand A, Grino M.

Eur J Endocrinol. 2006 Jul;155(1):177-85.

PMID:
16793965
15.

Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR.

Labuhn M, Vuaroqueaux V, Fina F, Schaller A, Nanni-Metellus I, Kung W, Eppenberger-Castori S, Martin PM, Eppenberger U.

Int J Biol Markers. 2006 Jan-Mar;21(1):30-9.

PMID:
16711511
16.

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

Cicenas J, Urban P, Küng W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S.

Eur J Cancer. 2006 Mar;42(5):636-45. Epub 2006 Jan 18.

PMID:
16414259
17.

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Küng W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S.

Breast Cancer Res. 2005;7(4):R394-401. Epub 2005 Mar 24.

18.

Expression of adrenomedullin in human ovaries, ovarian cysts and cancers. Correlation with estrogens receptor status.

Giacalone PL, Vuaroqueaux V, Daurés JP, Houafic L, Martin PM, Laffargue F, Maudelonde T.

Eur J Obstet Gynecol Reprod Biol. 2003 Oct 10;110(2):224-9.

PMID:
12969589
19.

Molecular cloning and tissue distribution of the ovine somatostatin receptor subtype 5: osst5.

Debus N, Dutour A, Boudouresque F, Vuaroqueaux V, Oliver C, Ouafik L.

Domest Anim Endocrinol. 2002 Oct;23(3):397-410.

PMID:
12206873
20.

Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.

Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brünner N, Martin PM.

Am J Pathol. 2002 Apr;160(4):1279-92.

21.

The ovine somatostatin receptor subtype 1 (osst1): partial cloning and tissue distribution.

Debus N, Dutour A, Vuaroqueaux V, Oliver C, Ouafik L.

Domest Anim Endocrinol. 2001 Aug;21(2):73-84.

PMID:
11585698
22.

Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma.

Vuaroqueaux V, Dutour A, Bourhim N, Ouafik L, Monges G, Briard N, Sauze N, Oliver C, Grino M.

J Mol Endocrinol. 2000 Jun;24(3):397-408.

PMID:
10828833
23.

No loss of sst receptors gene expression in advanced stages of colorectal cancer.

Vuaroqueaux V, Dutour A, Briard N, Monges G, Grino M, Oliver C, Ouafik L.

Eur J Endocrinol. 1999 Apr;140(4):362-6.

PMID:
10097257
24.

Hypothalamic mediated action of free fatty acid on growth hormone secretion in sheep.

Briard N, Rico-Gomez M, Guillaume V, Sauze N, Vuaroqueaux V, Dadoun F, Le Bouc Y, Oliver C, Dutour A.

Endocrinology. 1998 Dec;139(12):4811-9.

PMID:
9832417
25.

The human gastrin/cholecystokinin receptors: type B and type C expression in colonic tumors and cell lines.

Biagini P, Monges G, Vuaroqueaux V, Parriaux D, Cantaloube JF, De Micco P.

Life Sci. 1997;61(10):1009-18.

PMID:
9296339

Supplemental Content

Loading ...
Support Center